全身用药与疑似晚期或未控制原发性开角型青光眼的关联
基于美国保险理赔数据的数据库研究,将6130例需手术的POAG病例与30650例对照按年龄、性别和居住地区匹配,分析手术前5年处方药使用。选择性5-羟色胺再摄取抑制剂(SSRI)与POAG风险降低相关,钙通道阻滞剂与风险升高相关。
要点
- SSRI与需手术的POAG风险降低相关(OR 0.70,95%CI 0.64-0.76,P=1.0×10-15)
- 钙通道阻滞剂与需手术的POAG风险升高相关(OR 1.26,95%CI 1.18-1.35,P=1.8×10-11)
- 该研究为假设生成性研究,作者提出需进一步研究以评估关联
核心结论
- SSRI和钙通道阻滞剂与需手术的POAG存在潜在关联,作者提出需进一步研究以更好评估5-羟色胺代谢或钙通道与青光眼的关联,或确定关联是否源于处方模式差异。
研究设计与样本
- 数据库研究,纳入6130例POAG病例(定义为接受青光眼手术的POAG患者),按年龄、性别和居住地区匹配30650例对照(定义为接受白内障手术但无青光眼诊断、手术或用药编码的患者)。
- 计算参与者青光眼手术或白内障手术前5年内的处方药使用情况,对单个通用名药和药物类别分别用logistic回归评估与POAG状态的关联。
- 分析覆盖至少1%病例和对照中处方的所有通用名药和药物类别,并校正年龄、性别、居住地区、就业状态、保险计划类型和处方药总数。
主要发现
- 参与者中位年龄72岁,52%为女性。
- SSRI与POAG风险降低强相关(OR 0.70;95%CI 0.64-0.76;P=1.0×10-15),该类中最显著的药物为西酞普兰(OR 0.66;95%CI 0.57-0.77;P=1.2×10-7)。
- 钙通道阻滞剂与POAG风险升高强相关(OR 1.26;95%CI 1.18-1.35;P=1.8×10-11),该类中最显著的药物为氨氯地平(OR 1.27;95%CI 1.18-1.37;P=5.9×10-10)。
关键数值与推荐
- 共检验423个药物类别和1763种通用名药,共2186次统计学检验,Bonferroni校正显著性阈值为P<2.3×10-5。
- SSRI与POAG:OR 0.70(95%CI 0.64-0.76),P=1.0×10-15;西酞普兰OR 0.66(95%CI 0.57-0.77),P=1.2×10-7。
- 钙通道阻滞剂与POAG:OR 1.26(95%CI 1.18-1.35),P=1.8×10-11;氨氯地平OR 1.27(95%CI 1.18-1.37),P=5.9×10-10。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文报告该研究为假设生成性研究(hypothesis-generating study)。
- 作者在结论中提出需进一步研究(further research may be indicated)以更好评估5-羟色胺代谢或钙通道与青光眼的关联,或确定关联是否源于这些药物处方模式的差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify associations between systemic medications and primary open-angle glaucoma (POAG) requiring a procedure using United States insurance claims data in a hypothesis-generating study. DESIGN: Database study. PARTICIPANTS: In total, 6130 POAG cases (defined as patients with POAG undergoing a glaucoma procedure) were matched to 30 650 controls (defined as patients undergoing cataract surgery but without a coded glaucoma diagnosis, procedure, or medication) by age, gender, and region of residence. METHODS: Participant prescription drug use was calculated for the 5-year period before the glaucoma procedure or cataract surgery. Separately for individual generic drugs and drug classes, logistic regression was used to assess the association with POAG status. This was done across all generic drugs and drug classes that were prescribed in at least 1% of cases and controls. Analyses were adjusted for age, sex, region of residence, employment status, insurance plan type, and the total number of drugs prescribed. MAIN OUTCOME MEASURES: Odds ratio (OR) and 95% confidence intervals (CIs) for the association between each drug or drug class and POAG. RESULTS: The median age of participants was 72 years, and 52% were women. We tested for associations of POAG with 423 drug classes and 1763 generic drugs, resulting in a total of 2186 statistical tests and a Bonferroni-adjusted significance threshold of P < 2.3 × 10-5. Selective serotonin reuptake inhibitors (SSRIs) were strongly associated with a reduced risk of POAG (OR, 0.70; 95% CI, 0.64-0.76; P = 1.0 × 10-15); the most significant drug in this class was citalopram (OR, 0.66; 95% CI, 0.57-0.77; P = 1.2 × 10-7). Calcium channel blockers were strongly associated with an increased risk of POAG (OR, 1.26; 95% CI, 1.18-1.35; P = 1.8 × 10-11); the most significant drug in this class was amlodipine (OR, 1.27; 95% CI, 1.18-1.37; P = 5.9 × 10-10). CONCLUSIONS: We present data documenting potential associations of SSRIs and calcium channel blockers with POAG requiring a procedure. Further research may be indicated to better evaluate any associates of serotonin metabolism or calcium channels in glaucoma, or establish whether the associations are due to variations in the patterns for prescribing these drugs.
引用
- Zheng W, Dryja TP, Wei Z, et al. Systemic Medication Associations with Presumed Advanced or Uncontrolled Primary Open-Angle Glaucoma. Ophthalmology. 2018. PMID: 29433851. doi:10.1016/j.ophtha.2018.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。